Primary extragonadal germ cell tumor: A case report on prostate seminoma

Zheng,Wei; Wang,Lina; Yang,Deyong; Fang,Kun; Chen,Xiaochi; Wang,Xuejian; Li,Xiancheng; Li,Ziyao; Song,Xishuang; Wang,Jianbo

doi:10.3892/ol.2015.3592

Primary extragonadal germ cell tumor: A case report on prostate seminoma

Authors:
- Wei Zheng
- Lina Wang
- Deyong Yang
- Kun Fang
- Xiaochi Chen
- Xuejian Wang
- Xiancheng Li
- Ziyao Li
- Xishuang Song
- Jianbo Wang
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: August 11, 2015 https://doi.org/10.3892/ol.2015.3592
Pages: 2323-2326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary extragonadal germ cell tumors are rare, and 60% of such cases are seminomas. While the tumors can occur in the mediastinum, thymus, retroperitoneal organs and pineal gland, seminoma originating in the prostate tissue is extremely rare. The present study reports the case of a 54‑year‑old male with prostate seminoma. The patient was followed up at the First Affiliated Hospital of Dalian Medical University (Dalian, Liaoning, China) from 2001 onwards. The patient received chemotherapy with cyclophosphamide following total resection of the pelvic organs, pelvic lymph node dissection, continent detenial cecum‑ascending colic bladder and orchidectomy. The patient experienced considerable post‑operative quality of life for >10 years and the disease did not reappear. The study indicated that extragonadal seminoma is sensitive to chemotherapy, and that radical surgery and post‑operative adjuvant chemotherapy with cyclophosphamide is a reasonable and feasible treatment method.

View Figures

View References

1	Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, et al: Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 20:1864–1873. 2002. View Article : Google Scholar : PubMed/NCBI
2	KragJacobsen G, Barlebo H, Olsen J, et al: Testicular germ cell tumours in Denmark 1976–1980. Pathology of 1058 consecutive cases. Acta Radiol Oncol. 23:239–247. 1984. View Article : Google Scholar : PubMed/NCBI
3	Raghavan D: Testicular cancer: Maintaining the high cure rate. Oncology (Williston Park). 17:218–228; discussion, 228–229. 2003.PubMed/NCBI
4	Majewski W, Majewski S, Maciejewski A, et al: Adverse effects after radiotherapy for early stage (I, IIa, IIb) seminoma. Radiother Oncol. 76:257–263. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hashimoto T, Ohori M, Sakamoto N, Matsubayashi J, Izumi M and Tachibana M: Primary seminoma of the prostate. Int J Urol. 16:967–970. 2009. View Article : Google Scholar : PubMed/NCBI
6	Albany C and Einhorn LH: Extragonadal germ cell tumors: Clinical presentation and management. Curr Opin Oncol. 25:261–265. 2013.PubMed/NCBI
7	Stein ME, Charas T, Drumea K, Sabo E and Ben-Yosef R: Spermatocytic variant of classic seminoma: A report of five cases and a brief review of the literature. Rambam Maimonides Med J. 5:e00212014. View Article : Google Scholar : PubMed/NCBI
8	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
9	Peters JA, Beckjord EB, Banda Ryan DR, Carr AG, Vadaparampil ST, Loud JT, Korde L and Greene MH: Testicular cancer and genetics knowledge among familial testicular cancer family members. J Genet Couns. 17:351–364. 2008. View Article : Google Scholar : PubMed/NCBI
10	Utz DC and Buscemi MF: Extragonadal testicular tumors. J Urol. 105:271–274. 1971.PubMed/NCBI
11	Dueland S, Stenwig AE, Heilo A, Høie J, Ous S and Fosså SD: Treatment and outcome of patients with extragonadal germ cell tumours-the Norwegian Radium Hospital's experience 1979–94. Br J Cancer. 77:329–335. 1998. View Article : Google Scholar : PubMed/NCBI
12	Wallner LP, Frencher SK, Hsu JW, Chao CR, Nichol MB, Loo RK and Jacobsen SJ: Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int. 111:1245–1252. 2013. View Article : Google Scholar : PubMed/NCBI
13	Alapetite C, Brisse H, Patte C, et al: Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: The SFOP experience. Neuro Oncol. 12:1318–1325. 2010.PubMed/NCBI
14	Gerl A, Clemm C, Lamerz R and Wilmanns W: Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Cancer. 77:526–532. 1996. View Article : Google Scholar : PubMed/NCBI
15	Powles T, Robinson D, Shamash J, Moller H, Tranter N and Oliver T: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol. 19:443–447. 2008. View Article : Google Scholar : PubMed/NCBI
16	Horwich A: Stage I seminoma and carboplatin risks. Ann Oncol. 19:407–408. 2008. View Article : Google Scholar : PubMed/NCBI
17	Waxman DJ: Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res. 50:6449–6454. 1990.PubMed/NCBI
18	Shulman LN: The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am. 7:325–335. 1993.PubMed/NCBI
19	Choi YJ, Ok DW, Kwon DN, Chung JI, Kim HC, Yeo SM, Kim T, Seo HG and Kim JH: Murine male germ cell apoptosis induced by busulfan treatment correlates with loss of c-kit-expression in a Fas/FasL- and p53-independent manner. FEBS Lett. 575:41–51. 2004. View Article : Google Scholar : PubMed/NCBI
20	Schimenti KJ, Hanneman WH and Schimenti JC: Evidence for cyclophosphamide-induced gene conversion and mutation in mouse germ cells. Toxicol Appl Pharmacol. 147:343–350. 1997. View Article : Google Scholar : PubMed/NCBI